Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Clin Cancer Res. 2000 Jan;6(1):102-11. Unique Identifier : AIDSLINE MED/20120231
Rempel SA; Dudas S; Ge S; Gutierrez JA; Henry Ford Midwest Neuro-Oncology Center, Department of; Neurosurgery, Henry Ford Health Sciences Center, Detroit,; Michigan 48202, USA. nssan@neuro.hfh.edu


Abstract: Glioblastoma multiforme (GBM) tumors display extensive histomorphological heterogeneity, with great variability in the extent of invasiveness, angiogenesis, and necrosis. The identification of genes associated with these phenotypes should further the molecular characterization, permitting better definition of glioma subsets that may ultimately lead to better treatment strategies. Therefore, we performed a differential mRNA display analysis comparing six GBM-derived primary cell cultures from patients having tumors with varied histomorphological features. We identified stromal cell-derived factor 1 (SDF1) as a gene with varied expression. SDF1 (cytokine) and CXC chemokine receptor 4 (CXCR4) interactions are implicated in modulating cell migration. They are also implicated in modulating the immune response in AIDS patients by macrophage-mediated T-cell apoptosis. GBM patients also fail to mount an immune response, although their tumors are seemingly exposed to immune cells in regions of angiogenesis, where the blood-brain barrier is absent, or in areas of necrosis. To determine whether the expression and localization of SDF1 and CXCR4 are consistent with such a role in these brain tumors, immunohistochemical analyses of these proteins were performed on normal brain and astrocytomas (grades II-IV). In normal brain tissue, low levels of SDF1 (0.5+) were observed in astrocytic processes, in neurons, and in the occasional phagocytic cells around vessels. CXCR4 expression was negative in brain tissue but was observed in phagocytic cells within the vessel lumen. In tumors, SDF1 and CXCR4 expression was colocalized when both were expressed, and SDF1 and CXCR4 expression increased with increasing tumor grade (from 0.5+ to 6+). Additionally, CXCR4 was expressed in neovessel endothelial cells. The proteins were expressed in regions of angiogenesis and degenerative, necrotic, and microcystic changes. Those tumors displaying greater amounts of these features had greater staining intensity of the proteins. The expression of SDF1 and CXCR4 did not colocalize with the proliferation marker MIB-1. Thus, our data suggest that SDF1 and CXCR4 expressions: (a) increase with increasing grade; (b) colocalize to regions within these tumors where their interaction may contribute to angiogenesis and/or modulation of the immune response; and (c) may serve to characterize subsets of GBMs.


Keywords: JOURNAL ARTICLE Astrocytoma/BLOOD SUPPLY/GENETICS/IMMUNOLOGY/PATHOLOGY Brain Neoplasms/*BLOOD SUPPLY/GENETICS/IMMUNOLOGY/*PATHOLOGY Chemokines, CXC/*ANALYSIS/GENETICS Glioblastoma/*BLOOD SUPPLY/GENETICS/IMMUNOLOGY/*PATHOLOGY Human Immunohistochemistry Necrosis *Neovascularization, Pathologic Receptors, CXCR4/*ANALYSIS/GENETICS Reverse Transcriptase Polymerase Chain Reaction Tumor Cells, CulturedKWDjournalarticleastrocytoma/bloodsupply/genetics/immunology/pathologybrainneoplasms/KWDbloodsupply/genetics/immunology/KWDpathologychemokines,cxc/KWDanalysis/geneticsglioblastoma/KWDbloodsupply/genetics/immunology/KWDpathologyhumanimmunohistochemistrynecrosisKWDneovascularization,pathologicreceptors,cxcr4/KWDanalysis/geneticsreversetranscriptasepolymerasechainreactiontumorcells,cultured
000530
A0052173

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .